Uterine pleomorphic rhabdomyosarcoma in a patient receiving tamoxifen therapy

Gynecologic Oncology

Volumn 75, Issue 3, 1999, Pages 509-513

  Okada, Darren H ^a   Rowland, John B ^a   Petrovic, Lidija M ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; ENDOMETRIUM CANCER; FEMALE; HUMAN; MESENCHYMOMA; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RHABDOMYOSARCOMA; UTERUS SARCOMA;

EID: 0032778145     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5604     Document Type: Article

References (35)

1. Lancet. 339:1992;1-15.
2. Lerner L J, Jordan V C. Development of antiestrogens and their use in breast cancer: Eighth Cain memorial award lecture. Cancer Res. 50:1990;4177-4189.
3. Hoover R, Eversol R, Fraumeni J F, Myers M H. Cancer of the uterine corpus after hormonal treatment for breast cancer. Lancet. 1:1976;885.
4. Ismail S M. Pathology of endometrium treated with tamoxifen. J Clin Pathol. 47:1994;827-833.
5. Magriples U, Naftolin F, Schwartz P E, Carcangiu M L. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol. 11:1993;485-490.
6. Silva E G, Tornos C S, Follen-Mitchell M. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: The effects of tamoxifen. Int J Gynecol Pathol. 13:1994;248-258.
7. Carcangiu M L. Uterine pathology in tamoxifen treated patients with breast cancer. Anat Pathol. 2:1997;53-70.
8. Fisher B, Costantino J P, Redmond C K, Fisher E R, Wickerham D L, Cronin W M. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 86:1994;527-537.
9. Hardell L. Tamoxifen as risk factor for carcinoma of corpus uteri. Lancet. 2:1988;563.
10. Mignotte H, Sasco A J, Lasset C, Saez S, Rivoire M, Bobin J Y. Adjuvant therapy of breast cancer with tamoxifen and endometrial carcinoma. Bull Cancer. 79:1992;969-977.
11. Altaras M M, Aviram R, Cohen I, Cordoba M, Yarkoni S, Beyth Y. Role of prolonged stimulation of tamoxifen therapy in the etiology of endometrial sarcomas. Gynecol Oncol. 49:1993;255-258.
12. Clarke M R. Uterine malignant mixed mullerian tumor in a patient on long-term tamoxifen therapy for breast cancer. Gynecol Oncol. 51:1993;411-415.
13. Fornander T, Hellstrom A, Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst. 85:1993;1850-1855.
14. Seoud M AF, Johnson J, Weed J C Jr. Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol. 82:1993;165-169.
15. Barakat R R, Wong G, Curtin J P, Vlamis V, Hoskins W J. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol. 55:1994;164-168.
16. Evans M J, Langlois N EI, Kitchener H C. Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed mullerian tumor) of the uterus? Int J Gynecol Cancer. 5:1995;310-313.
17. Sasco A J, Raffi F, Satge D, Goburdhun J, Fallouh B, Leduc B. Endometrial mullerian carcinosarcoma after cessation of tamoxifen therapy for breast cancer. Int J Gynaecol Obstet. 48:1995;307-310.
18. Clement P B, Oliva E, Young R H. Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: A report of six cases and a review of tamoxifen-associated endometrial lesions. Int J Gynecol Pathol. 15:1996;222-229.
19. Bocklage T, Lee K R, Belinson J L. Uterine mullerian adenosarcoma following adenomyoma in a woman on tamoxifen therapy. Gynecol Pathol. 44:1992;104-109.
20. Pang L C. Endometrial stromal sarcoma with sex cord-like differentiation associated with tamoxifen therapy. South Med J. 91:1998;592-594.
21. Beer T W, Buchanan R, Buckley C H. Uterine stromal sarcoma following tamoxifen treatment. J Clin Pathol. 48:1995;596.
22. Eddy G, Mazur M T. Endolymphatic stromal myosis associated with tamoxifen use. Gynecol Oncol. 64:1997;262-264.
23. McCluggage W G, Varma M, Weir P, Bharucha H. Uterine leiomyosarcoma in patient receiving tamoxifen therapy. Acta Obstet Gynecol Scand. 75:1996;593-595.
24. Hsu S M, Raine L, Fanger H. The use of antibody and avidin-biotin-peroxidase complex in immunoperoxidase techniques. Am J Clin Pathol. 75:1981;816-821.
25. Daniel W W, Koss L G, Brunschwig A. Sarcoma botryoides of the vagina. Cancer. 12:1959;74-84.
26. Podczaski E, Sees J, Kaminski P. Rhabdomyosarcoma of the uterus in a postmenopausal patient. Gynecol Oncol. 37:1990;439-442.
27. Hart W R, Craig J R. Rhabdomyosarcomas of the uterus. Am J Clin Pathol. 70:1978;217-223.
28. Chumas J C, Mann W J, Tseng L. Malignant mixed mullerian tumor of the endometrium in a young woman with polycystic ovaries. Cancer. 52:1983;1478-1481.
29. Altaras M M, Jaffe R, Cohen I, Gruber A, Yanai-Inbar I, Bernheim J. Role of prolonged excessive estrogen stimulation in the pathogenesis of endometrial sarcomas: Two cases and a review of the literature. Gynecol Oncol. 38:1990;273-277.
30. Soper J T, McCarty K S, Hinshaw W, Creasman W T, McCarty K S, Clarke-Pearson D L. Cytoplasmic estrogen and progesterone receptor content of uterine sarcomas. Am J Obstet Gynecol. 150:1984;342-348.
31. Tosi P, Sforza V, Santopietro R. Estrogen receptor content immunohistochemically determined by monoclonal antibodies, in endometrial stromal sarcoma. Obstet Gynecol. 73:1989;75-78.
32. Williams G M, Iatropoulos M J, Djordjevic M V, Kaltenberg O P. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis. 14:1993;315-317.
33. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res. 53:1993;3919-3924.
34. Hard, G, C, Iatropoulos, M, J, Jordan, K, Radi, L, Kaltenberg, O, P, Imondi, A, R, Williams, G, M: Cancer Res53:4534-4541, 1993.
35. Han X, Liehr J G. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res. 52:1992;1360-1363.